Supporting Real-World Achievement of Treat-to-Target in IBD: Scalable Strategies for Integrating Objective Markers of Inflammation and Patient-Reported Monitoring in Routine Clinical Practice

Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.

Start Activity

Format

ActionED

Time to Complete

3.00 hr(s).

Release Date

October 15, 2026

Expires On

October 15, 2027

Selecting, intensifying, sequencing, or combining therapies in IBD can be challenging for clinicians, especially considering the number of novel targeted therapies available and the expanding role of patient-reported outcomes in individualization of therapeutic decision-making. Advance your IBD management through implementation of recommended treat-to-target strategies. Start with an individualized assessment to determine the strengths and gaps in your current practice, then review educational content according to your needs. Reinforce your learning through practical guidance (eg, interactive patient cases and faculty commentary) and downloadable tools and resources that you can apply in daily practice. strengthen use of patient-reported outcomes, biomarker monitoring, and quality-of-life evaluation, then reinforce learning through case-based modules, expert faculty examples, and practice tools such as workflows and implementation templates.

This educational activity is designed for gastroenterologists, gastroenterology APPs, specialty and clinical pharmacists, and other members of the multidisciplinary team managing patients with IBD.

Upon completion of this activity, learners will be able to:

Implement the use of patient-reported outcomes to assess disease activity and monitor treatment response to optimize long-term management of IBD
Integrate objective markers of inflammation with patient-reported outcomes to facilitate comprehensive, individualized management of patients with IBD
Apply strategies for addressing quality of life impacts of IBD to enhance patient care

The Impact of IBD

IBD epidemiology and clinical characteristics
Disease burden in IBD

Treatment Options and Monitoring Methods

Overview of advanced therapies for moderate-to-severe IBD
Tools and methods for assessing IBD: subjective measures
Tools and methods for assessing IBD: biomarkers
Tools and methods for assessing IBD: endoscopy, MRI, and CT
Tools and methods for assessing IBD: intestinal ultrasound

Recommendations for Employing a Treat-to-Target Strategy

STRIDE-II: treat-to-target recommendations in IBD

Initial Treatment Selection

Guidelines for CD
Guidelines for UC
Additional considerations for initial treatment selection
Optimizing therapy and treatment sequencing

Multidisciplinary Care Pathways

Multidisciplinary team strategies
Pharmacists in multidisciplinary care of IBD
Advanced practice providers in multidisciplinary care of IBD

Provided by the Academy for Continued Healthcare Learning (ACHL).

Supported by an educational grant from Lilly.

Ashwin N. Ananthakrishnan, MD, MPH (Chair)
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Shubha Bhat, PharmD, MS, BCACP, FCCP

Clinical Pharmacist – Gastroenterology/Hepatology

Departments of Pharmacy and Digestive Disease Institute

Cleveland Clinic

Cleveland, OH

Kimberly Orleck, PA-C

Atlanta Gastroenterology Associates

Vice President of Advanced Practice Providers,

United Digestive

Atlanta, GA

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

The following financial relationships have been provided:

Ashwin N. Ananthakrishnan, MD, MPH: Grant/Research Support: Takeda

Shubha Bhat, PharmD, MS, BCACP, FCCP: Consultant: Eli Lilly, Johnson & Johnson

Kimberly Orleck, PA-C: Consultant: AbbVie, Cristcot, Takeda. Speakers Bureau: AbbVie, Ardelyx, Janssen, Pfizer, Salix, Takeda

Millie D. Long, MD, MPH (reviewer): Consultant: AbbVie, BMS, Celltrion, Genentech, Intercept, Janssen, Lilly, Merck, Pfizer, Prometheus, Roche, Roivant, Spyre, Sanofi, Takeda, Target RWE

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Clinicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: azathioprine, methotrexate, mercaptopurine, and systemic corticosteroids are not approved for the treatment of IBD.

To receive credit, learners are required to complete a baseline assessment; design, develop, and implement an action plan using our automated platform; view online interventions; and return after 30 days to report progress in making system-level changes. A thorough response to the reflection questionnaire on your involvement in the quality improvement activity is also required for meaningful participation. A certificate will be available upon completion of the reflection questionnaire. There is no fee to participate in the activity or for the generation of the certificate.

Partial credit may not be awarded for CPE credit; participation in the complete activity is required to receive credit. CPE credit will be submitted to CPE Monitor® on the first business day of each month.

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity has been approved for 3.0 contact hours.

ACPE Universal Activity Number: 0396-9999-26-020-H99-P

Activity Type: Application

Release Date: October 15, 2026

Expiration Date: October 15, 2027

Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.

Nora Eldasher
neldasher@achlcme.org

Supporting Real-World Achievement of Treat-to-Target in IBD: Scalable Strategies for Integrating Objective Markers of Inflammation and Patient-Reported Monitoring in Routine Clinical Practice

Program Description

Intended Audience

Learning Objectives

Meeting Schedule

Provider Information

Supporter Information

Faculty

Faculty Disclosure

Staff Disclosure

Disclaimer

Method of Participation

Accreditation and Credit Designation

Program Manager

Related Activities